Psoriasis and Lichen planus: Coexistence in a Single Patient

Shiohara, Tetsuo; Hayakawa, Jun; Nagashima, Masaji

doi:10.1159/000248355

Cited by 16 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other bowel diseases occasionally described concomitant with LP include coeliac disease (Lundstrom et al, 1982;Fortune and Buchanan, 1993) and Crohn's disease (Kano et al, 1995), though others have not found these associations . (14) MISCELLANEOUS ASSOCIATIONS LP has occasionally been associated with other conditions, including psoriasis (Shiohara et al, 1989;Naldi et al, 1990;Delaney et al, 1993), lichen sclerosis , urolithiasis (Halevy and Feuerman, 1983), agents used to treat gallstones (Ellul et al, 1992), mesangioproliferative glomerulonephritis (Cottoni et al, 1988), erythema dyschromicum (Berger et al, 1989), and Turner's syndrome with endocrinopathies (Kurgansky and Burnett, 1994).…”

Section: (8) Stressmentioning

confidence: 99%

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

468

461

View full text Add to dashboard Cite

Lichen planus (LP) is a relatively common disorder of the stratified squamous epithelia, which is, in many ways, an enigma. This paper is the consensus outcome of a workshop held in Switzerland in 1995, involving a selection of clinicians and scientists with an interest in the condition and its management. The oral (OLP) eruptions usually have a distinct clinical morphology and characteristic distribution, but OLP may also present a confusing array of patterns and forms, and other disorders may clinically simulate OLP. Lesions may affect other mucosae and/or skin. Lichen planus is probably of multifactorial origin, sometimes induced by drugs or dental materials, often idiopathic, and with an immunopathogenesis involving T-cells in particular. The etiopathogenesis appears to be complex, with interactions between and among genetic, environmental, and lifestyle factors, but much has now been clarified about the mechanisms involved, and interesting new associations, such as with liver disease, have emerged. The management of lichen planus is still not totally satisfactory, and there is as yet no definitive treatment, but there have been advances in the control of the condition. There is no curative treatment available; immunomodulation, however, can control the condition. Based on the observed increased risk of malignant development, OLP patients should be offered regular follow-up examination from two to four times annually and asked to report any changes in their lesions and/or symptoms. Follow-up may be particularly important in patients with atrophic/ulcerative/erosive affections of the tongue, the gingiva, or the buccal mucosa. Much more research is required into the genetic and environmental aspects of lichen planus, into the premalignant potential, and into the possible associations with chronic liver, and other, disorders. More clinical studies are required into the possible efficacy of immunomodulatory drugs such as pentoxifylline and thalidomide.

show abstract

Section: (8) Stressmentioning

confidence: 99%

Update On Oral Lichen Planus: Etiopathogenesis and Management

Scully

Beyli²,

Ferreiro

et al. 1998

Critical Reviews in Oral Biology & Medicine

468

461

View full text Add to dashboard Cite

show abstract

“…Some authors speculated about an underlying imbalance of TNF‐α and IFN‐γ as a result of an antigenic stimulus that caused superimposed linear LP lesions in a psoriatic patient . Local production of IFN‐γ was assigned to an improvement of psoriasis during development of LP in another case report . Apart from well‐described T‐cellular inflammatory mechanisms in psoriasis, high activation of innate immune pathways may lead to enhanced epidermal antigen release which could pave the way to an anti‐epithelial reaction and development of other inflammatory skin diseases.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept

Niebel

Wilsmann‐Theis

Wenzel

2020

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis vulgaris and lichen planus are distinct T‐cell‐driven inflammatory skin diseases. Both present in a variety of clinical subtypes. Mucosal or nail involvement may be present. Here, we report the rare concomitant clinical presentation of psoriatic arthritis and annular atrophic lichen planus on the trunk of a 52‐year‐old male patient. Treatment with sulfasalazine failed to control inflammatory activity; methotrexate and leflunomide were ceased due to side‐effects. After confirmation of both diagnoses, we initiated a tumor necrosis factor (TNF)‐α‐directed therapy with the fusion protein etanercept resulting in significant improvement of both conditions. This case report aims to highlight the rare colocalization of psoriasis and lichen planus, the rare entity of annular atrophic lichen planus, and to discuss a possible beneficial impact of certain TNF‐α inhibitors on subtypes of lichen planus.

show abstract

“…The coexistence of psoriasis and typical LP has been rarely reported (4, 5). It has been suggested that this coexistence LP is probably underreported in the literature (4). The reasons for such association remain obscure.…”

Section: Discussionmentioning

confidence: 99%

“…The coexistence of psoriasis with typical LP or bullous pemphigoid has been previously reported (4–7), but the reason for such association remains obscure. However, a central role for T‐cell mediated autoimmunity has been suggested for all three disorders.…”

Section: Introductionmentioning

confidence: 99%